熱門資訊> 正文

GT Bizerma报告第二季度业绩

2026-08-14 20:10

GT Biopharma(GTBP) 0

GT Biopharma press release (GTBP): Q2 net loss for the second quarter of 2026 of approximately $4.5 million, compared to $30.2 million for the same comparable quarter of 2025.
The Company had cash and cash equivalents of approximately $5.1 million as of June 30, 2026, which is anticipated to be sufficient to fund the Company’s operations through the fourth quarter of 2026.

More on GT Biopharma

Seeking Alpha’s Quant Rating on GT Biopharma
Historical earnings data for GT Biopharma
Financial information for GT Biopharma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。